The high NQO1/Catalase ratios in pancreatic cancers strongly suggest that NQO1-overexpressing PDA cancer cells will respond to NQO1 bioactivatable drugs by producing supralethal doses of H2O2. The gene discussed is NQO1; the disease is Patent ductus arteriosus.